ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis-Reference-Cited by-同舟云学术

ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis

Published:2019-03-27 Issue: Volume:10 Page:
ISSN:1664-2295
Container-title:Frontiers in Neurology
language:
Short-container-title:Front. Neurol.

Author:

Lingor Paul,Weber Markus,Camu William,Friede Tim,Hilgers Reinhard,Leha Andreas,Neuwirth Christoph,Günther René,Benatar Michael,Kuzma-Kozakiewicz Magdalena,Bidner Helen,Blankenstein Christiane,Frontini Roberto,Ludolph Albert,Koch Jan C.,

Funder

Bundesministerium für Bildung und Forschung

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Ministère des Affaires Sociales, de la Santé et des Droits des Femmes

National Center for Advancing Translational Sciences

Publisher

Frontiers Media SA

Subject

Neurology (clinical),Neurology

Reference20 articles.

1. ROCK inhibition in models of neurodegeneration and its potential for clinical translation;Koch;Pharmacol Ther.,2018

2. Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases;Dong;Drug Discov Today.,2010